: iStockAnalyst.com Symbols Feed

Partnerships And Mergers Updates : Wipro Partners with BP, Endo Buys US Rights to Fortesta, Siemens Buys China Metal, Google's Search for Italian Solution

Fri, 28 Aug 2009 18:10:58 GMT

Wipro Technologies, the IT services business of Wipro Ltd. (WIT) announced that it has entered into a five year agreement with BP Plc. (BP) to provide IT Applications Development and Maintenance services for BP’s Fuels Value Chain and Corporate businesses across the globe. Endo Pharmaceuticals (ENDP) signed an agreement with UK-based ProStrakan Group Plc to acquire exclusive rights to commercialize Fortesta in the U.S., where the product is currently under Food and Drug Administration (FDA) review. Siemens Energy, a division of Siemens AG (SI), acquired the majority holding in the Chinese metalworking company Yangtze Delta Manufacturing and the Chinese aluminum foundry GISAP (GIS Steel & Aluminium Products), both headquartered in Hangzhou. The Italian Federation of Newspaper Publishers recently filed an anti-trust complaint against Google Inc. (GOOG). This prompted the Italian Competition Authority to search Google’s Milan offices on Thursday, pursuant to a probe that was ini[More...]

Be Prepared For These Huge Biotech Catalysts In September

Fri, 21 Aug 2009 15:16:00 GMT

Biotech stocks are the most volatile in the world. One-day jumps of 200% and overnight crashes of 90% are commonplace. The biggest culprit behind biotech volatility? The United States Food and Drug Administration, the FDA. Before ending up on pharmacy shelves, every new drug needs to pass through a series of regulatory hurdles dictated by the FDA. Without the FDA's blessing, a drug – no matter how great it may be – cannot make it to market. So an FDA approval can help propel the stock 30% or more. A rejection could send the stock tumbling as much as 90%. Because of this, biotech traders love taking a position ahead of FDA rulings... Which means next month is shaping up to be one of the most event-packed months for biotech traders. I've highlighted six major FDA decisions in the next month below: Date Company FDA Action Drug –[More...]

Trading FDA Decisions with Calendar Spreads

Fri, 17 Jul 2009 02:55:42 GMT

Trading FDA Decisions with Calendar Spreads Joe Kunkle, The Investment U Research Team FDA approvals/rejections of drugs can make or break a Biotech company. These decisions can be incredibly volatile and profitable if you’re positioned correctly. There have been instances where shares lose more than three-fourths of its value and other cases where a company rises 900% or more in a single day (like Vanda Pharmaceuticals recently). In most instances, it’s pretty clear when the FDA will make a decision on a key drug, often named the PDUFA[More...]

FDA Calendar Updates: Auxilium Pharma (NASDAQ:AUXL)

Thu, 18 Jun 2009 20:37:27 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response lette (...)[More...]

BioMedReports FDA Calendar: 19 Hot Summer Trades

Wed, 17 Jun 2009 12:13:04 GMT

Below is a sample of entries from the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The companies outlined below have expected FDA new drug product decisions or clinical trial results expected over the next three months of summer. The list also includes some Extreme Trades of companies with market caps below $250 million that have pending clinical trial results or FDA decisions that could have a major stock price impact. Rigel Pharma (NASDAQ:RIGL): On 5/5/09, (...)[More...]

BioMedReports.com Extreme Trades: ACAD, ANPI, BSTC, RPRX, SNTS

Tue, 09 Jun 2009 19:20:33 GMT

Below are four companies with market caps under $200 million (all financial data current as of 6/9/09 during intraday trading) which have pending FDA decisions and/or clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in Extreme FDA and Clinical Trial Calendar Trades, which are highlighted (...)[More...]

Pharmaceuticals & Biotech - Industry Outlook

Tue, 09 Jun 2009 12:05:35 GMT

The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including: Pfizer (PFE, 7.5x), Eli Lilly (LLY,[More...]

FDA, Clinical Trial Updates: WPI, UTHR, AUXL, DNDN

Wed, 29 Apr 2009 14:55:11 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 5 (...)[More...]

Pharmaceuticals

Tue, 10 Feb 2009 18:38:00 GMT

Large pharmaceutical companies all seem to be in a similar boat heading into 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds as well. Revenue growth is non-existent, and earnings growth is being driven primarily by cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including Pfizer (PFE, 7x), Eli Lilly (LLY, 9x), Merck ([More...]

Top 40 Rated Emerging Bio-Pharma Stocks

Mon, 22 Dec 2008 16:22:00 GMT

The accompanying table (click to enlarge) highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators (ETFI) Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return. The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq[More...]

Shawn Cross Joins Burrill Merchant Banking

Thu, 18 Jun 2009 16:46:00 GMT

SAN FRANCISCO, June 18 /CNW/ -- Burrill & Company, a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media, is pleased to announce that Shawn Cross has joined the firm as Managing Director, Merchant Banking.
In addition, Shawn will make an important contribution to the collective efforts of the Burrill Merchant Banking Team in the formation and deployment of Burrill Private Equity funds.
Shawn brings considerable experience in life science investment banking including:

: iStockAnalyst.com Symbols Feed

Partnerships And Mergers Updates : Wipro Partners with BP, Endo Buys US Rights to Fortesta, Siemens Buys China Metal, Google's Search for Italian Solution

Be Prepared For These Huge Biotech Catalysts In September

Trading FDA Decisions with Calendar Spreads

FDA Calendar Updates: Auxilium Pharma (NASDAQ:AUXL)

BioMedReports FDA Calendar: 19 Hot Summer Trades

BioMedReports.com Extreme Trades: ACAD, ANPI, BSTC, RPRX, SNTS

Pharmaceuticals & Biotech - Industry Outlook

FDA, Clinical Trial Updates: WPI, UTHR, AUXL, DNDN

Pharmaceuticals

Top 40 Rated Emerging Bio-Pharma Stocks

Shawn Cross Joins Burrill Merchant Banking

Testosterone gel causes safety concerns

Auxilium Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference

Auxilium Pharmaceuticals to Announce Third Quarter 2009 Results and Conduct Conference Call on Wednesday, October 28, 2009

Jefferies Expands International Healthcare Investment Banking Platform

Auxilium Pharmaceuticals Completes Sale of 3.45 Million Shares of Common Stock Resulting in $115.7 Million in Net Proceeds

Auxilium Pharmaceuticals, Inc. Announces Pricing of a Public Offering of Common Stock

Auxilium Pharmaceuticals to Present at the UBS Global Life Sciences Conference

Auxilium Pharmaceuticals to Present at the Thomas Weisel Partners 2009 Healthcare Conference

BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results

Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results and Operational Highlights

Auxilium Pharmaceuticals, Inc. Secures $30 Million Revolving Credit Line With Silicon Valley Bank

Form 4 LANGER DENNIS For: Sep 30 (10K)

Form 4 FUCHS RENATO For: Sep 30 (10K)

Form 4 FETZER OLIVER For: Sep 30 (10K)

Form 4 Stacey Jennifer Evans For: Sep 14 (10K)

Form 4 Graham Roger D Jr For: Sep 14 (10K)

Form 4 Fickenscher James E For: Sep 14 (10K)

Form 4 ANIDO ARMANDO For: Sep 11 (10K)

Form 4 Fickenscher James E For: Sep 08 (10K)

Form 4 Stacey Jennifer Evans For: Jul 24 (10K)

Form 4 Graham Roger D Jr For: Jul 24 (10K)